HPSI0813i-ffdr_3
WTSIi207-A
General
Cell Line |
|
hPSCreg name | WTSIi207-A |
Cite as: | WTSIi207-A (RRID:CVCL_AH00) |
Alternative name(s) |
HPSI0813i-ffdr_3
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 20th January 2021 |
User feedback | |
Provider |
|
Generator | Wellcome Sanger Institute (WTSI) |
Distributors | |
External Databases |
|
BioSamples | SAMEA2201451 |
HipSci | HPSI0813i-ffdr_3 |
Cellosaurus | CVCL_AH00 |
Wikidata | Q54891372 |
General Information |
|
Publications | |
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 45-49 |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://ega-archive.org/datasets/EGAD00001001932
Methylation profiling
https://ega-archive.org/datasets/EGAD00010001139
SNP typing array
https://ega-archive.org/datasets/EGAD00010001147 |
External Databases (Donor) |
|
BioSamples | SAMEA2444537 |
HipSci | HPSI-fpdr |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Willem Ouwehand, Cambridge BioResource |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | No |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | No |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | NRES Committee Yorkshire & The Humber - Leeds West |
Approval number | 15/YH/0391 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | NRES Committee Yorkshire & The Humber - Leeds West |
Approval number | 15/YH/0391 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Age of donor (at collection) | 45-49 |
Collected in | 2013 |
Source cell line vendor | Cambridge BioResource |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Genes | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Feeder cells |
Mouse embryo fibroblast (MEF) feeder cells |
Passage method |
Enzymatically
Collagenase and Dispase
|
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium:
Main protein source: Knock-out serum replacement Serum concentration: % |
Characterisation
Analysis of Undifferentiated Cells
Pluripotency Score | Novelty Score | |
25.769 | 1.156 |
Report
HPSI-fpdr.pluritest.pluripotency_score.20170510.png
pluripotency image
HPSI-fpdr.pluritest.novelty_score.20170510.png
novelty image
Transcriptome Characterisation
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
Sox17 |
Yes |
Protocol or reference
IFforgermlayermarkershIPSCsWTSIi207-A.jpg
Immunostaining
In vitro spontaneous differentiation
Marker | Expressed |
Brachyuri |
Yes |
Protocol or reference
IFforgermlayermarkershIPSCsWTSIi207-A.jpg
Immunostaining
Neuroectoderm
In vitro spontaneous differentiation
Marker | Expressed |
Sox1 |
Unknown |
Protocol or reference
IFforgermlayermarkershIPSCsWTSIi207-A.jpg
Immunostaining
Microbiology / Virus Screening |
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://ega-archive.org/datasets/EGAD00001001932
Methylation profiling
https://ega-archive.org/datasets/EGAD00010001139
SNP typing array
https://ega-archive.org/datasets/EGAD00010001147
cnv
http://www.hipsci.org/lines/#/lines/HPSI0813i-ffdr_3 Number of regions different from primary tissue: 0; Length of differences from primary tissue: 0
Methylation profiling
https://ega-archive.org/datasets/EGAD00010001139 Text file with probe intensities |
Login to share your feedback, experiences or results with the research community.